IL-6R - Tocilizumab

In IIM, IL-6 biology and early human experience with IL-6 receptor blockade created a reasonable mechanistic rationale for tocilizumab, but the “signal” has depended heavily on phenotype and study design. The most supportive preliminary prospective data come from a 6-month, one-arm open-label pilot in refractory immune-mediated necrotizing myopathy (IMNM) (anti-SRP or anti-HMGCR): 11 adults received tocilizumab 8 mg/kg IV every 4 weeks × 6 and were assessed with the 2016 ACR/EULAR myositis response criteria (Total Improvement Score, TIS). Seven of 11 (63.6%) met response (TIS ≥20) and by 6 months 7/11 achieved “major improvement”; the median TIS was 50 at 3 months and 75 at 6 months. In the subset with repeat biopsies (n=5 responders), necrotic fibers decreased (2.36% → 0.6%, p=0.0028) and regenerating (CD56+) fibers decreased (5.98% → 1.16%, p=0.0007), consistent with improved regenerative pathology; higher baseline serum IL-6 and muscle IL-6 mRNA (plus higher CD56+ fiber % at baseline) tracked with better TIS, suggesting a potential biomarker-enriched strategy if IL-6 blockade is pursued further in IMNM.

The best “established” efficacy dataset in classic IIM is the multicenter phase 2B randomized, double-blind, placebo-controlled trial in refractory adult dermatomyositis (DM) and polymyositis (PM) (“TIM”): 36 subjects (DM 23, PM 13) were randomized 18:18 to tocilizumab 8 mg/kg IV or placebo every 4 weeks for 24 weeks.

The primary endpoint (TIS trajectory from weeks 4–24) was negative: mean (SD) TIS on treatment was 26.4 (16.8) for tocilizumab vs 29.3 (16.8) for placebo (P=0.86), with no meaningful separation by subset (DM vs PM). Secondary endpoints (time to minimal/moderate/major improvement; time to worsening; changes in core set measures; steroid-sparing) were also not significantly different; a notable feature was a substantial improvement trend in both arms (placebo effect / background therapy optimization). Safety looked broadly comparable: adverse events occurred in 8/18 (44.4%) on tocilizumab vs 6/18 (33.3%) on placebo (total events 14 vs 9; no significant difference).

Putting these together, tocilizumab’s clinical-trial story in IIM is best described as phenotype-contingent but unproven for refractory DM/PM: the controlled trial did not demonstrate benefit over placebo, while the IMNM pilot suggests a possible niche where muscle regeneration/IL-6–linked biology may matter more (especially anti-SRP/anti-HMGCR disease) and where biomarker enrichment could reduce dilution by non-IL-6–driven pathways. The negative RCT also highlights design problems that repeatedly blunt myositis trials—heterogeneous baselines, subjective/effort-dependent measures, and strong placebo/background-care effects—arguing that any future IL-6 blockade work should pair stricter activity thresholds, objective endpoints (e.g., quantitative strength testing, imaging, or validated skin metrics), and molecular selection rather than treating “IIM” as a single drug-responsive entity.

References (numbered as cited)

1. Oddis CV, Rockette HE, Zhu L, et al. Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis. ACR Open Rheumatology. 2022;4(11):983–990. doi:10.1002/acr2.11493.
2. Li S, Wang L, et al. The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study. Frontiers in Pharmacology. 2021. doi:10.3389/fphar.2021.635654.
3. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis (TIM) (Protocol/registration materials; NCT02043548).

Links

1) https://pmc.ncbi.nlm.nih.gov/articles/PMC9661830/

https://pubmed.ncbi.nlm.nih.gov/36128663/

https://doi.org/10.1002/acr2.11493

2) https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.635654/full

https://pubmed.ncbi.nlm.nih.gov/33815117/

https://doi.org/10.3389/fphar.2021.635654

3) https://clinicaltrials.gov/study/NCT02043548

https://cdn.clinicaltrials.gov/large-docs/48/NCT02043548/Prot_SAP_000.pdf